FRES:NSD-Fresh2 Group Ltd (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 0.85

Change

0.00 (0.00)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.47 (+0.61%)

USD 120.60B
REGN Regeneron Pharmaceuticals Inc

+2.21 (+0.31%)

USD 84.94B
ARGX argenx NV ADR

+2.05 (+0.33%)

USD 36.54B
ALNY Alnylam Pharmaceuticals Inc

-0.75 (-0.31%)

USD 31.66B
BGNE BeiGene Ltd

+3.06 (+1.68%)

USD 20.24B
UTHR United Therapeutics Corporatio..

+3.23 (+0.90%)

USD 16.18B
MRNA Moderna Inc

+0.16 (+0.40%)

USD 16.10B
RPRX Royalty Pharma Plc

+0.17 (+0.67%)

USD 15.27B
SMMT Summit Therapeutics PLC

+0.28 (+1.47%)

USD 13.67B
INCY Incyte Corporation

-0.35 (-0.50%)

USD 13.52B

ETFs Containing FRES

AGMI Themes Silver Miners ETF 5.04 % 0.00 %

+0.13 (+0.52%)

USD 0.55M
SILJ Amplify ETF Trust 3.74 % 0.69 %

-0.01 (0.52%)

USD 0.64B
SILG:LSE Global X Silver Miners UC.. 2.89 % 0.00 %

N/A

N/A
SILV:LSE Global X Silver Miners UC.. 2.89 % 0.00 %

N/A

N/A
SIL Global X Silver Miners ET.. 0.00 % 0.65 %

+0.26 (+0.52%)

N/A
SILV:SW GLOBAL X SILVER MINERS UC.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -90.45% 6% D- 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -90.45% 6% D- 3% F
Trailing 12 Months  
Capital Gain -89.21% 7% C- 4% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -89.21% 7% C- 4% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -17.25% 23% F 14% F
Dividend Return -17.25% 23% F 14% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 45.22% 68% D+ 42% F
Risk Adjusted Return -38.14% 25% F 17% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector